Chapter 1 · Part 4: Why Everything You Were Told About Testosterone Is Dangerously Wrong#

The most expensive error in medical history isn’t a drug that went wrong. It’s a hypothesis that was never properly tested, got written into treatment guidelines anyway, and then ran unchallenged for decades—blocking millions of people from effective care while the evidence quietly piled up in the opposite direction.

Three assumptions have dominated the conversation around testosterone for most of modern medicine’s existence. Each one entered the medical consensus through the same three-step process: an influential paper, a citation by an authoritative body, a line in a clinical guideline. And once a claim is in the guideline, overturning it costs far more—politically, institutionally, professionally—than simply leaving it there.

This isn’t about conspiracy theories. It’s about learning to ask a simple question most patients never think to ask: What is the evidence level behind this recommendation?

Myth One: Testosterone Causes Prostate Cancer#

In 1941, Charles Huggins observed that castrating men with metastatic prostate cancer caused their tumors to regress. He published his findings, and in 1966 he received a Nobel Prize. The medical establishment then built half a century of clinical practice on a conclusion extrapolated from that work: testosterone fuels prostate cancer, therefore reducing testosterone prevents or treats it.

The original study involved two patients.

Two. Not two hundred. Not two thousand. Two men with advanced metastatic disease whose tumors responded to the removal of androgen signaling. The observation was real. The extrapolation—that testosterone causes prostate cancer in healthy men—was a leap that outran the data by a spectacular margin.

Decades later, Abraham Morgentaler’s saturation model offered a framework that actually matched the clinical evidence. Androgen receptors in prostate tissue reach saturation at relatively low testosterone concentrations. Below the saturation point, changes in testosterone do affect prostate tissue. Above it, the relationship flatlines. More testosterone does not mean more stimulation. The receptors are already fully occupied.

Large-scale trials—the REDUCE trial, the Prostate Cancer Prevention Trial, and multiple meta-analyses involving tens of thousands of men—have consistently failed to show that higher testosterone levels increase prostate cancer incidence. A comprehensive safety review published by MSN synthesizing decades of research confirmed that testosterone replacement therapy does not elevate prostate cancer risk in monitored patients, further dismantling the decades-old assumption. Meanwhile, accumulating evidence suggests that men in the lowest quartile of testosterone may face higher rates of aggressive, high-grade prostate cancer.

The hypothesis was never proven. It was assumed.

Myth Two: Testosterone Replacement Increases Cardiovascular Risk#

In 2010, a clinical trial known as TOM (Testosterone in Older Men with Mobility Limitations) was stopped early due to an apparent increase in cardiovascular events in the testosterone group. Headlines erupted. The FDA issued warnings. Doctors grew reluctant to prescribe testosterone replacement therapy.

What most of the coverage failed to mention: the study enrolled men averaging seventy-four years old, most of whom already had significant cardiovascular disease or multiple risk factors. The sample was small. The testosterone doses were high relative to the population’s baseline. And the study wasn’t designed to assess cardiovascular safety as a primary endpoint.

It took over a decade for a definitive answer. The TRAVERSE trial, published in 2023, was specifically built to evaluate cardiovascular safety of testosterone replacement. It enrolled over five thousand men with established or high risk for cardiovascular disease. The result: testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo.

One poorly designed study created a global panic. One well-designed study took thirteen years to undo the damage. The institutional machinery does not self-correct quickly.

Myth Three: Hormonal Decline Is Natural and Doesn’t Need Intervention#

“Your testosterone is declining because you’re getting older. That’s natural.”

This statement is true in the same way tooth decay, vision loss, and bone density reduction are natural consequences of aging. Nobody argues we should accept cataracts without treatment because failing eyesight is a natural part of getting older. Nobody tells a patient with osteoporosis to simply accept fragile bones as the body’s intended trajectory.

Yet when it comes to hormonal decline, the medical establishment applies a different standard. The assumption is that because testosterone drops with age in most men, this decline is not only expected but acceptable—even desirable to leave untreated. This is normalization bias: the tendency to treat a widespread phenomenon as inherently normal and therefore not worth addressing.

The confusion is compounded by shifting diagnostic goalposts. As the Pharmaceutical Journal recently reported, evolving diagnostic criteria for testosterone deficiency have sparked controversy among clinicians—with some arguing that narrower thresholds leave symptomatic men untreated, while others warn that broadening the criteria risks overdiagnosis. When the line between “low” and “normal” keeps moving, patients are left stranded in the gap between guidelines and lived experience.

“Common” is not the same as “optimal.” A seventy-year-old man with the testosterone levels of a healthy fifty-year-old is not medically abnormal. He’s medically fortunate. The question isn’t whether decline happens—it does. The question is whether that decline produces symptoms, reduces quality of life, and increases disease risk. In a significant percentage of aging men, the answer to all three is yes.

The Correlation Trap#

Ice cream sales and drowning deaths are highly correlated. Nobody concludes that ice cream causes drowning. The confounding variable—summer heat—drives both.

This reasoning is obvious in everyday life. In medical research, the same logical error happens constantly, with far greater consequences.

When a study reports that “low testosterone is associated with cardiovascular disease,” the association is real. But the causal direction isn’t obvious. Men with low testosterone also tend to be more overweight, more sedentary, more stressed, and sleeping less. These confounding variables are each independently associated with cardiovascular risk. Is low testosterone the cause, the consequence, or simply a fellow traveler with the real culprits?

Reverse causation adds another layer. Perhaps it’s not that low testosterone causes obesity—perhaps obesity causes low testosterone, through increased aromatase activity converting testosterone to estradiol in fat tissue. The direction you assume determines the intervention you choose. Get it backward, and you treat the wrong thing.

Disentangling correlation from causation requires controlled experiments, adequate sample sizes, and independent replication. Most of the alarming headlines about testosterone are based on observational studies that cannot establish causation at all. They can generate hypotheses. They cannot confirm them.

The Evidence Pyramid#

Not all research is created equal. A case report—one doctor describing one patient’s experience—sits at the bottom of the evidence hierarchy. It’s an anecdote with a medical degree. An observational study is a step up but can’t control for confounders. A randomized controlled trial isolates the variable of interest. A systematic review or meta-analysis pools data from multiple trials to find the signal through the noise.

When someone tells you “a study found that testosterone increases heart attack risk,” the first question isn’t “really?” It’s “what kind of study?” A case report and a multi-center randomized trial with five thousand participants are both “studies.” The gap in evidence strength between them is like the gap between one person’s diary and a national census.

Medical guidelines should be built on the top of the pyramid. Too often, they’re built on the middle or the bottom—and then defended as if they came from the top.

The Media Distortion Machine#

Between a published paper and the headline you read, there are multiple layers of distortion. The original paper reports a modest, conditional finding with appropriate caveats. The press release simplifies it. The journalist simplifies the press release. The editor writes a headline designed to generate clicks, not accuracy.

“Testosterone therapy may be associated with a non-significant trend toward increased cardiovascular events in a subpopulation of elderly men with pre-existing conditions” becomes “Testosterone Therapy Linked to Heart Attacks.” Same study. Completely different message.

Health news accuracy research consistently finds that the majority of medical news stories fail to adequately discuss the quality of evidence, the absolute magnitude of risks and benefits, or the existence of alternative interpretations. You’re not reading science. You’re reading a game of telephone played between scientists, PR departments, journalists, and algorithms optimized for engagement.

Three Questions That Change Everything#

Independent thinking isn’t about becoming a conspiracy theorist or dismissing medical advice wholesale. It’s about building a filter—a small set of questions that separate well-supported conclusions from institutional inertia.

Question one: What is the evidence level? Is this based on a case report, an observational study, or a randomized controlled trial? The answer determines how much weight the conclusion deserves.

Question two: How large was the sample? Two patients is not evidence. Two hundred is preliminary. Two thousand starts to be meaningful. Twenty thousand with replication across multiple sites is solid.

Question three: Has it been independently replicated? A single study, no matter how well designed, is a hypothesis until someone else reproduces the result. Replication is what separates a finding from a fluke.

Apply these three questions to the myths above. Huggins’ prostate cancer hypothesis: evidence level—case report; sample size—two; replication—contradicted by subsequent large trials. The TOM cardiovascular scare: evidence level—a trial stopped early, not designed for the endpoint in question; contradicted by the purpose-built TRAVERSE trial.

You don’t need a medical degree to ask these questions. You need the habit of asking them. That habit is the foundation of cognitive sovereignty—the refusal to outsource your understanding to assumptions that have never been properly tested.

Stop accepting verdicts from trials that never happened.